Arcturus Therapeutics Enhances mRNA Vaccine Production Through Strategic Partnerships and Innovations

Arcturus Therapeutics Advances mRNA Vaccine Manufacturing Through Strategic Collaboration

Arcturus Therapeutics Holdings Inc., a pioneering company in the field of messenger RNA (mRNA) medicines, is currently expanding its operational capabilities through strategic partnerships and technological innovations. The company participates in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference in New York, where it highlights its commitment to developing vaccines and therapies for infectious diseases and rare conditions. Arcturus, founded in 2013 and based in San Diego, has established itself as a leader in the mRNA therapeutic landscape with its proprietary technologies, including LUNAR® lipid-mediated delivery and STARR® mRNA Technology.

A significant aspect of Arcturus's recent activities includes its collaboration with CSL Seqirus and the establishment of a joint venture named ARCALIS in Japan. This joint venture focuses on the manufacturing of mRNA vaccines and therapeutics, a critical development given the global demand for innovative solutions to combat infectious diseases. At the core of this partnership is the self-amplifying mRNA vaccine, KOSTAIVE®, which has received approval for domestic manufacturing in Japan. This approval allows for the production of active pharmaceutical ingredients at ARCALIS's facilities, which will then be formulated and distributed by Meiji Seika Pharmatech Co., Ltd. This integrated infrastructure not only enhances the production capabilities within Japan but also reflects the global trend towards localized vaccine manufacturing.

Dr. Pad Chivukula, COO of Arcturus, expresses optimism about the approval and the synergy created through the joint venture. He emphasizes the importance of transferring next-generation technologies, including their proprietary LUNAR® lipid nanoparticle formulation and STARR® sa-mRNA manufacturing processes, to facilitate the effective production of KOSTAIVE®. This innovative approach to vaccine development, where self-amplifying mRNA enables the body to generate more mRNA and proteins, represents a significant step forward in enhancing immune responses against diseases like COVID-19. As Arcturus continues to build on its robust patent portfolio of over 400 patents, it positions itself as a key player in the evolving landscape of mRNA therapeutics.

In addition to its manufacturing advancements, Arcturus is actively engaged in a diverse pipeline that includes RNA therapeutic candidates for conditions such as ornithine transcarbamylase deficiency and cystic fibrosis, alongside partnered mRNA vaccine programs targeting SARS-CoV-2 and influenza. The company encourages stakeholders to stay informed through its Investor Relations platform and social media channels.

Overall, Arcturus Therapeutics is at the forefront of mRNA medicine innovation, leveraging strategic collaborations and cutting-edge technology to enhance vaccine production and therapeutic development, thereby addressing critical public health challenges.